Medy-Tox Inc. (086900.KQ)
KRW 124900.0
(-2.42%)
KRW 124900.0
(-2.42%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 221.12 Billion KRW | 13.34% |
| 2022 | 195.09 Billion KRW | 5.53% |
| 2021 | 184.86 Billion KRW | 31.27% |
| 2020 | 140.82 Billion KRW | -31.6% |
| 2019 | 205.9 Billion KRW | 0.22% |
| 2018 | 205.44 Billion KRW | 13.36% |
| 2017 | 181.23 Billion KRW | 36.01% |
| 2016 | 133.25 Billion KRW | 50.56% |
| 2015 | 88.5 Billion KRW | 16.62% |
| 2014 | 75.89 Billion KRW | 93.89% |
| 2013 | 39.14 Billion KRW | 7.94% |
| 2012 | 36.26 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 54.58 Billion KRW | -19.73% |
| 2024 Q2 | 65 Billion KRW | 19.08% |
| 2023 Q2 | 51.78 Billion KRW | 21.36% |
| 2023 FY | 221.12 Billion KRW | 13.34% |
| 2023 Q4 | 68 Billion KRW | 15.94% |
| 2023 Q1 | 42.67 Billion KRW | -18.36% |
| 2023 Q3 | 58.65 Billion KRW | 13.26% |
| 2022 Q3 | 53.31 Billion KRW | 7.14% |
| 2022 FY | 195.09 Billion KRW | 5.53% |
| 2022 Q4 | 52.26 Billion KRW | -1.96% |
| 2022 Q2 | 49.75 Billion KRW | 25.15% |
| 2022 Q1 | 39.75 Billion KRW | 1.36% |
| 2021 FY | 184.86 Billion KRW | 31.27% |
| 2021 Q1 | 31.82 Billion KRW | 7.7% |
| 2021 Q2 | 43.94 Billion KRW | 38.09% |
| 2021 Q3 | 69.87 Billion KRW | 59.01% |
| 2021 Q4 | 39.22 Billion KRW | -43.87% |
| 2020 Q3 | 35.79 Billion KRW | -13.95% |
| 2020 Q4 | 29.54 Billion KRW | -17.45% |
| 2020 FY | 140.82 Billion KRW | -31.6% |
| 2020 Q2 | 41.59 Billion KRW | 22.74% |
| 2020 Q1 | 33.88 Billion KRW | -41.82% |
| 2019 FY | 205.9 Billion KRW | 0.22% |
| 2019 Q1 | 44.25 Billion KRW | 1.92% |
| 2019 Q2 | 55.03 Billion KRW | 24.36% |
| 2019 Q4 | 58.25 Billion KRW | 20.45% |
| 2019 Q3 | 48.36 Billion KRW | -12.12% |
| 2018 Q4 | 43.42 Billion KRW | -10.01% |
| 2018 FY | 205.44 Billion KRW | 13.36% |
| 2018 Q3 | 48.24 Billion KRW | -12.22% |
| 2018 Q2 | 54.96 Billion KRW | -6.54% |
| 2018 Q1 | 58.81 Billion KRW | 11.01% |
| 2017 Q3 | 40.31 Billion KRW | -15.07% |
| 2017 Q1 | 40.47 Billion KRW | 1.26% |
| 2017 Q2 | 47.47 Billion KRW | 17.28% |
| 2017 Q4 | 52.97 Billion KRW | 31.41% |
| 2017 FY | 181.23 Billion KRW | 36.01% |
| 2016 Q4 | 39.97 Billion KRW | 21.11% |
| 2016 Q3 | 33 Billion KRW | 4.73% |
| 2016 Q2 | 31.51 Billion KRW | 9.57% |
| 2016 Q1 | 28.76 Billion KRW | 15.94% |
| 2016 FY | 133.25 Billion KRW | 50.56% |
| 2015 Q2 | 21.86 Billion KRW | 16.29% |
| 2015 Q1 | 18.8 Billion KRW | 30.85% |
| 2015 Q4 | 24.8 Billion KRW | 7.73% |
| 2015 Q3 | 23.02 Billion KRW | 5.32% |
| 2015 FY | 88.5 Billion KRW | 16.62% |
| 2014 Q1 | 13.3 Billion KRW | 45.01% |
| 2014 Q4 | 14.36 Billion KRW | -55.3% |
| 2014 Q2 | 16.07 Billion KRW | 20.78% |
| 2014 Q3 | 32.14 Billion KRW | 99.98% |
| 2014 FY | 75.89 Billion KRW | 93.89% |
| 2013 Q2 | 11.08 Billion KRW | 25.81% |
| 2013 Q4 | 9.17 Billion KRW | -8.91% |
| 2013 FY | 39.14 Billion KRW | 7.94% |
| 2013 Q1 | 8.8 Billion KRW | -18.09% |
| 2013 Q3 | 10.07 Billion KRW | -9.09% |
| 2012 FY | 36.26 Billion KRW | 0.0% |
| 2012 Q4 | 10.75 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| HLB Co., Ltd. | 42.9 Billion KRW | -415.426% |
| iNtRON Biotechnology, Inc. | 9.58 Billion KRW | -2206.838% |
| BINEX Co., Ltd. | 154.82 Billion KRW | -42.82% |
| Bioneer Corporation | 263.23 Billion KRW | 15.999% |
| Anterogen.Co.,Ltd. | 6.5 Billion KRW | -3301.726% |
| MEDIPOST Co., Ltd. | 68.64 Billion KRW | -222.131% |
| CrystalGenomics, Inc. | 4.87 Billion KRW | -4432.403% |
| Helixmith Co., Ltd | 4.2 Billion KRW | -5162.745% |
| Chabiotech Co.,Ltd. | 953.95 Billion KRW | 76.821% |
| Peptron, Inc. | 3.34 Billion KRW | -6516.629% |
| Amicogen, Inc. | 159.9 Billion KRW | -38.283% |
| Genexine, Inc. | 4.42 Billion KRW | -4895.241% |
| HLB Therapeutics Co.,Ltd. | 53.74 Billion KRW | -311.394% |
| LegoChem Biosciences, Inc. | 34.14 Billion KRW | -547.581% |
| ALTEOGEN Inc. | 96.52 Billion KRW | -129.086% |
| PharmaResearch Co., Ltd. | 261.01 Billion KRW | 15.283% |
| SillaJen, Inc. | 3.93 Billion KRW | -5512.829% |
| JETEMA, Co., Ltd. | 58.71 Billion KRW | -276.593% |
| OliX Pharmaceuticals,Inc | 17.06 Billion KRW | -1195.811% |
| Genomictree Inc. | 3.41 Billion KRW | -6369.283% |
| MedPacto, Inc. | - KRW | -Infinity% |
| D&D Pharmatech | 18.67 Billion KRW | -1083.917% |
| EASY BIO,Inc. | 165.38 Billion KRW | -33.7% |
| GI Innovation, Inc. | 5.31 Billion KRW | -4057.303% |